SE0200895D0 - New pharmaceutical composition - Google Patents
New pharmaceutical compositionInfo
- Publication number
- SE0200895D0 SE0200895D0 SE0200895A SE0200895A SE0200895D0 SE 0200895 D0 SE0200895 D0 SE 0200895D0 SE 0200895 A SE0200895 A SE 0200895A SE 0200895 A SE0200895 A SE 0200895A SE 0200895 D0 SE0200895 D0 SE 0200895D0
- Authority
- SE
- Sweden
- Prior art keywords
- pharmaceutical composition
- new pharmaceutical
- relates
- drug delivery
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glanulating (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Steroid Compounds (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0200895A SE0200895D0 (sv) | 2002-03-22 | 2002-03-22 | New pharmaceutical composition |
ARP030100860A AR038951A1 (es) | 2002-03-22 | 2003-03-12 | Particulas porosas, fabricacion y uso para la elaboracion de un medicamento |
EP03745055A EP1490033A1 (en) | 2002-03-22 | 2003-03-20 | No-donating nsaids adsorbed into carrier particles |
PCT/SE2003/000468 WO2003080029A1 (en) | 2002-03-22 | 2003-03-20 | No-donating nsaids adsorbed into carrier particles |
JP2003577859A JP2005533751A (ja) | 2002-03-22 | 2003-03-20 | 担体粒子に吸着されたno−供与nsaid |
UY27727A UY27727A1 (es) | 2002-03-22 | 2003-03-20 | Nueva composicion farmacéutica- |
US10/507,368 US20050129774A1 (en) | 2002-03-22 | 2003-03-20 | Non-donating nsaids adsorbed into carrier particles |
TW092106166A TW200307564A (en) | 2002-03-22 | 2003-03-20 | New pharmaceutical composition |
AU2003216006A AU2003216006A1 (en) | 2002-03-22 | 2003-03-20 | No-donating nsaids adsorbed into carrier particles |
JP2010171855A JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたno−供与nsaid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0200895A SE0200895D0 (sv) | 2002-03-22 | 2002-03-22 | New pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0200895D0 true SE0200895D0 (sv) | 2002-03-22 |
Family
ID=20287374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0200895A SE0200895D0 (sv) | 2002-03-22 | 2002-03-22 | New pharmaceutical composition |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050129774A1 (sv) |
EP (1) | EP1490033A1 (sv) |
JP (2) | JP2005533751A (sv) |
AR (1) | AR038951A1 (sv) |
AU (1) | AU2003216006A1 (sv) |
SE (1) | SE0200895D0 (sv) |
TW (1) | TW200307564A (sv) |
UY (1) | UY27727A1 (sv) |
WO (1) | WO2003080029A1 (sv) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
AU2003293987B2 (en) | 2002-12-20 | 2010-09-09 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
SE0301880D0 (sv) * | 2003-06-25 | 2003-06-25 | Astrazeneca Uk Ltd | New drug delivery composition |
EP1682092A2 (en) * | 2003-11-13 | 2006-07-26 | Alza Corporation | Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer |
JP5694645B2 (ja) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーNiconovum Ab | 改善された嗅ぎたばこ組成物 |
WO2008101064A1 (en) * | 2007-02-14 | 2008-08-21 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist |
WO2009012425A2 (en) * | 2007-07-19 | 2009-01-22 | Logigal Therapeutics, Inc. | Compositions including leukotriene antagonists and nsaids and methods of using the same |
WO2009149053A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Naproxcinod process and solid dispersion |
WO2010031552A1 (en) * | 2008-09-17 | 2010-03-25 | Niconovum Ab | Process for preparing snuff composition |
DE102010052847A1 (de) | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
AU2014322985B2 (en) * | 2013-09-20 | 2019-05-16 | Tillotts Pharma Ag | Delayed release pharmaceutical formulation |
EP3222273B1 (en) | 2014-11-18 | 2019-09-25 | National Institute for Materials Science | Method for producing porous particle |
GB201502073D0 (en) | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | HDEG technology |
GB201502077D0 (en) * | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | Improved hme technology |
WO2023212063A1 (en) * | 2022-04-29 | 2023-11-02 | Freeman John J | Method and composition for treating lung diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2700141B2 (ja) * | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤 |
JPH08301763A (ja) * | 1995-04-28 | 1996-11-19 | Dainippon Pharmaceut Co Ltd | 易溶性粉末状医薬組成物およびその製造方法 |
WO2000038655A1 (en) * | 1998-12-23 | 2000-07-06 | Alza Corporation | Dosage forms comprising porous particles |
NZ530701A (en) * | 1999-06-04 | 2005-09-30 | Alza Corp | Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel |
US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
JP2001316248A (ja) * | 2000-02-28 | 2001-11-13 | Eisai Co Ltd | 油状薬物含有組成物の製造方法 |
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
-
2002
- 2002-03-22 SE SE0200895A patent/SE0200895D0/sv unknown
-
2003
- 2003-03-12 AR ARP030100860A patent/AR038951A1/es not_active Application Discontinuation
- 2003-03-20 EP EP03745055A patent/EP1490033A1/en not_active Withdrawn
- 2003-03-20 WO PCT/SE2003/000468 patent/WO2003080029A1/en active Application Filing
- 2003-03-20 US US10/507,368 patent/US20050129774A1/en not_active Abandoned
- 2003-03-20 AU AU2003216006A patent/AU2003216006A1/en not_active Abandoned
- 2003-03-20 UY UY27727A patent/UY27727A1/es not_active Application Discontinuation
- 2003-03-20 JP JP2003577859A patent/JP2005533751A/ja not_active Withdrawn
- 2003-03-20 TW TW092106166A patent/TW200307564A/zh unknown
-
2010
- 2010-07-30 JP JP2010171855A patent/JP2010285445A/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003216006A1 (en) | 2003-10-08 |
AR038951A1 (es) | 2005-02-02 |
EP1490033A1 (en) | 2004-12-29 |
WO2003080029A1 (en) | 2003-10-02 |
TW200307564A (en) | 2003-12-16 |
UY27727A1 (es) | 2003-10-31 |
US20050129774A1 (en) | 2005-06-16 |
JP2010285445A (ja) | 2010-12-24 |
JP2005533751A (ja) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0200895D0 (sv) | New pharmaceutical composition | |
MX2009003030A (es) | Forma galenita para la administracion por via transmucosa de principios activos. | |
RS51569B (en) | COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL | |
ATE302616T1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
MXPA04008068A (es) | Metodo para administrar moleculas de glp-1. | |
DK1487416T3 (da) | Lægemiddelmikropartikler | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
MX2009005727A (es) | Nanoparticulas de entidad anfifilica. | |
DE60322371D1 (de) | Volumensparende arzneiform zur kontrollierten freisetzung | |
DE60138468D1 (de) | Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen | |
TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
WO2006102990A3 (de) | Wafer enthaltend steroidhormone | |
BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
EP2279732A3 (en) | Compounds and compositions for delivering active agents | |
DK1796650T3 (da) | Transport- og afgivelsesvehikel indeholdende nanopartikler | |
WO2008087323A3 (fr) | Forme galenique pour l'administration par voie trans-muqueuse de paracetamol | |
MXPA06011467A (es) | Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). | |
AR051589A1 (es) | Agentes terapeuticos | |
MY143563A (en) | New association of an if sinusoidal current inhibitor and a calcium channel-blocking agent, and pharmaceutical ingredients containing said association | |
WO2003028624A3 (en) | Levothyroxine compositions and methods | |
WO2006137856A3 (en) | Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility | |
UY30126A1 (es) | Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones | |
ATE439125T1 (de) | Fenofibrate tablett und verfahren zur herstellung |